{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:51Z","timestamp":1791478251317,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jhep.2025.11.009","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:58:01Z","timestamp":1764003481000},"page":"702-712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A single-arm phase IIIb study of 8-week glecaprevir\/pibrentasvir treatment in adults with acute hepatitis C"],"prefix":"10.1016","volume":"84","author":[{"given":"Josep M.","family":"Llibre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0686-6537","authenticated-orcid":false,"given":"Christoph","family":"Boesecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhi","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7895","authenticated-orcid":false,"given":"Patrick M.","family":"Lank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6597-0727","authenticated-orcid":false,"given":"Michael G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7596-0784","authenticated-orcid":false,"given":"Linda M.","family":"Fredrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Welhaven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Semizarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9408-1889","authenticated-orcid":false,"given":"John","family":"Marcinak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5199-8451","authenticated-orcid":false,"given":"Ivan","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3278-7138","authenticated-orcid":false,"given":"Massimo","family":"Puoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2025.11.009_bib1","series-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","year":"2024"},{"key":"10.1016\/j.jhep.2025.11.009_bib2","unstructured":"Centers for Disease Control. Hepatitis C surveillance. https:\/\/www.cdc.gov\/hepatitis-surveillance-2022\/hepatitis-c\/. Accessed: February 3, 2025."},{"key":"10.1016\/j.jhep.2025.11.009_bib3","unstructured":"European Centre for Disease Prevention and Control. Hepatitis C. In: ECDC. Annual epidemiological report for 2022. Stockholm: ECDC. Accessed."},{"key":"10.1016\/j.jhep.2025.11.009_bib4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/sti.2003.008532","article-title":"Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase?","volume":"80","author":"Browne","year":"2004","journal-title":"Sex Transm Infections"},{"key":"10.1016\/j.jhep.2025.11.009_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/jvh.13665","article-title":"The 'Viennese epidemic' of acute HCV in the era of direct-acting antivirals","volume":"29","author":"Chromy","year":"2022","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.11.009_bib6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2012.07.007","article-title":"Case definitions for acute hepatitis C virus infection: a systematic review","volume":"57","author":"Hajarizadeh","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.11.009_bib9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.11.009_bib10","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series(\u2606)","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.11.009_bib11","series-title":"Impact of directly acting-antivirals and behavior change due to the COVID 19 pandemic on HCV micro-elimination in MSM in Germany","author":"Ingiliz","year":"2023"},{"key":"10.1016\/j.jhep.2025.11.009_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.726419","article-title":"A tale of two viruses: immunological insights into HCV\/HIV coinfection","volume":"12","author":"Gobran","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2025.11.009_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12954-023-00780-3","article-title":"Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs","volume":"20","author":"Hassan","year":"2023","journal-title":"Harm Reduction J"},{"key":"10.1016\/j.jhep.2025.11.009_bib16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/hep.30501","article-title":"The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA","volume":"70","author":"Coyle","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.11.009_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12879-021-05928-9","article-title":"Exploring and understanding HCV patient journeys - HEPCARE Europe project","volume":"21","author":"Glaspy","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhep.2025.11.009_bib18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0040-1713657","article-title":"Simplification of care for chronic hepatitis C virus infection","volume":"40","author":"Pawlotsky","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2025.11.009_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.29611","article-title":"Should we treat acute hepatitis C? A decision and cost-effectiveness analysis","volume":"67","author":"Bethea","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.11.009_bib20","series-title":"Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030","year":"2022"},{"issue":"Suppl 3","key":"10.1016\/j.jhep.2025.11.009_bib21","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1093\/cid\/ciad344","article-title":"Direct-acting antiviral therapy for treatment of acute and recent hepatitis C virus infection: a narrative review","volume":"77","author":"Martinello","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2025.11.009_bib22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2021.04.056","article-title":"Sofosbuvir\/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection","volume":"75","author":"Matthews","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2025.11.009_bib23","article-title":"Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: the HepNet acute HCV-V study","volume":"5","author":"Maasoumy","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2025.11.009_bib24","article-title":"Effectiveness and safety of glecaprevir\/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: a single-arm retrospective study","author":"Pol","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.11.009_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.31003","article-title":"Short-duration pan-genotypic therapy with glecaprevir\/pibrentasvir for 6 weeks among people with recent hepatitis C viral infection","volume":"72","author":"Martinello","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2025.11.009_bib26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/2050640619835394","article-title":"High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients","volume":"7","author":"Chromy","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2025.11.009_bib27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2025.11.009_bib28","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/jvh.12429","article-title":"Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort","volume":"22","author":"Doyle","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.11.009_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/jvh.13757","article-title":"Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination","volume":"30","author":"Bryce","year":"2023","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2025.11.009_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002876","article-title":"Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics","volume":"9","author":"Magiorkinis","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.jhep.2025.11.009_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009916","article-title":"Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data","volume":"17","author":"Danesh","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhep.2025.11.009_bib32","article-title":"Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing","volume":"15","author":"Li","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2025.11.009_bib33","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciz022","article-title":"Safety and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1\u20136 hepatitis C virus infections and compensated liver disease","volume":"69","author":"Gane","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2025.11.009_bib34","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.3748\/wjg.v13.i41.5481","article-title":"Clinical significance of activity of ALT enzyme in patients with hepatitis C virus","volume":"13","author":"Akkaya","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2025.11.009_bib35","doi-asserted-by":"crossref","first-page":"14562","DOI":"10.1073\/pnas.1210592109","article-title":"Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis","volume":"vol 109","author":"Farci","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jhep.2025.11.009_bib36","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/cid\/ciz025","article-title":"Safety of hepatitis C viral protease inhibitors in compensated cirrhotics: lingering concerns put to rest?","volume":"69","author":"Kiser","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2025.11.009_bib37","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1007\/s12325-024-02996-6","article-title":"Updated results from the retrospective CREST Study on the safety and effectiveness of 8-week glecaprevir\/pibrentasvir in HCV-infected treatment-na\u00efve patients with compensated cirrhosis","volume":"41","author":"Cornberg","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jhep.2025.11.009_bib38","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3390\/v14071541","article-title":"Real-world safety, effectiveness, and patient-reported outcomes in patients with chronic hepatitis C virus infection treated with glecaprevir\/pibrentasvir: updated data from the German Hepatitis C-Registry (DHC-R)","volume":"14","author":"Cornberg","year":"2022","journal-title":"Viruses"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782502625X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882782502625X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:56:19Z","timestamp":1777528579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882782502625X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S016882782502625X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2025.11.009","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single-arm phase IIIb study of 8-week glecaprevir\/pibrentasvir treatment in adults with acute hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2025.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}